Rapport d’étude de marché sur l’immunothérapie par virus oncolytiques par type de cancer (mélanome, cancer du poumon, cancer du sein, cancer colorectal, cancer de la prostate), par type de virus (virus de l’herpès simplex, adénovirus, réovirus, virus de la vaccinie, virus de la maladie de Newcastle), par voie d’administration (intratumorale, intraveineuse, intrapéritonéale, sous-cutanée), par technologie (virus génétiquement modifié, virus de type sauvage) et par région (Amérique du Nord, Europe, Amérique du Sud, Asie) Pacifique, Moyen-Orien...

The Oncolytic Virus Immunotherapy Market is expected to be valued at 26.39 USD billion in 2034.

The projected CAGR for the Oncolytic Virus Immunotherapy Market from 2025 to 2034 is 19.62%.

North America is anticipated to dominate the Oncolytic Virus Immunotherapy Market with a value of 7.68 USD billion in 2032.

The market valuation for Melanoma in the Oncolytic Virus Immunotherapy Market was 0.92 USD billion in 2023.

Major players in the Oncolytic Virus Immunotherapy Market include AbbVie, Fortress Biotech, Oncolytics Biotech, and Bristol-Myers Squibb.

The expected market size for Breast Cancer in the Oncolytic Virus Immunotherapy Market is projected to be 3.095 USD billion by 2032.

The market for Colorectal Cancer in the Oncolytic Virus Immunotherapy Market is expected to be valued at 1.812 USD billion in 2032.

The market size for the APAC region in the Oncolytic Virus Immunotherapy Market was 0.56 USD billion in 2023.

The growth potential for Lung Cancer in the Oncolytic Virus Immunotherapy Market is significant, with an expected increase to 2.718 USD billion by 2032.

The market size for Prostate Cancer in the Oncolytic Virus Immunotherapy Market was 0.603 USD billion in 2023.